Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer

Lung Cancer

Volumn 43, Issue 2, 2004, Pages 195-201

  Sakai, Hiroshi ^a   Yoneda, Shuichi ^a   Kobayashi, Kunihiko ^a   Komagata, Hiroshi ^a   Kosaihira, Seiji ^a   Kazumoto, Tomoko ^a   Saito, Yoshihiro ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Carboplatin; Concurrent chemoradiotherapy; Docetaxel; Non small cell lung cancer

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; STEROID;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGITIS; FEMALE; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; VOMITING;

EID: 1642452719     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.08.021     Document Type: Article

References (20)

1. Furuse K., Fukuoka M., Kawahara M.et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J. Clin. Oncol. 17:1999;2692-2699.
2. Curran W.J., Scott C., Langer C.et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc. Am. Soc. Clin. Oncol. 19:2000;484a. [Abstract 1891].
3. Choy H., Rodriguez F., Koester S.et al. Synergistic effects of Taxol/Taxotere on radiation sensitivity of human cell lines. Int. J. Radiat. Oncol. Biol. Phys. 24(Suppl 1):1993;1059.
4. Manson K.A., Hunter N.R., Milas M.et al. Docetaxel enhances tumor radioresponse in vivo. Clin. Cancer Res. 3:1997;2431-2438.
5. Douple E.B., Richmond R.C., O'Hara J.A.et al. Carboplatin as a potentiator of radiation therapy. Cancer Treat. Rep. 12:1985;111-124.
6. Koukourakis M.I., Kourousis C., Kamilaki M.et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur. J. Cancer. 34:1998;833-844.
7. Mauer A.N., Masters G.A., Haraf D.J.et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J. Clin. Oncol. 16:1998;159-164.
8. Segawa Y., Ueoka H., Kiura K.et al. A phase I/II study of docetaxel (TXT) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (LA-NSCLC). Proc. Am. Soc. Clin. Oncol. 19:2000;508a. [Abstract 1988].
9. Choy H., DeVore R.F., Hande K.R.et al. Phase I trial of outpatient weekly docetaxel carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) trial. Lung Cancer. 34:2001;441-449.
10. Choy H., Akerley W., Safran H.et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. J. Clin. Oncol. 16:1998;3316-3322.
11. Sakai H., Yoneda S., Kobayashi K.et al. A phase I/II study of bi-weekly docetaxel (DOC) and carboplatin (CBDCA) with concurrent thoracic radiation therapy (TRT) followed by consolidation chemotherapy with DOC/CBDCA for stage III unresectable non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;238b. [Abstract 2704].
12. Choy H., Curran W.J., Scott C.B.et al. Preliminary report of locally advanced multimodality protocol (LAMP): ACR427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc. Am. Soc. Clin. Oncol. 21:2002;291a. [Abstract 1160].
13. Gandara D.R., Chansky K., Albain K.S.et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small cell lung cancer: Phase II Southwest Oncology Group Study S9504. J. Clin. Oncol. 21:2003;2004-2010.
14. Rodriguez J., Pawel A., Pluzanska V.et al. A multicenter randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (Dcb) vs. vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;314a. [Abstract 1251].
15. Law A., Daly B., Madsen M.et al. High incidence of isolated brain metastases (CNS Mets) following complete response (CR) in advanced non-small cell lung cancer (NSCLC): a new challenge. Proc. Am. Soc. Clin. Oncol. 16:1997;447a. [Abstract 1604].
16. Andre F., Grunenwald D., Pujol J.L.et al. Patterns of relapse of N2 nonsmall cell lung carcinoma in patients treated with preoperative chemotherapy: Should prophylactic cranial irradiation be considered? Cancer. 91:2001;2394-2400.
17. Stuschke M., Eberhardt W., Pöttgen C.et al. Prophylactic cranial irradiation in locally advanced non-small cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J. Clin. Oncol. 17:1999;2700-2709.
18. Cox J.D., Stanley K., Petrovich Z., Paig C., Yesner R. Cranial irradiation in cancer of the lung of all cell types. JAMA. 245(5):1981;469-472.
19. Russell A.H., Pajak T.E., Selim H.M.et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int. J. Rad. Onc. Biol. Phys. 21(3):1991;637-643.
20. Umsawasdi T., Valdivieso M., Chen T.T.et al. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J. Neuro-Oncol. 2(3):1984;253-259.